Organovo’s Drug Significantly Reduces Liver Fat In NASH Study

London: Organovo Holdings’ experimental drug reduced liver fat by as much as 22.8% in a mid-stage study of some patients with non-alcoholic steatohepatitis (NASH), fueling optimism over its chances to enter a potential multi-billion dollar market.

Shares of the small biotech firm surged 44% to $1.45 in early trading on Monday after the company reported the data for the oral drug, FXR314.

Patients with NASH, which was last year renamed metabolic function-associated steatohepatitis (MASH), have an excess build-up of fat in the liver, leading to inflammation and scarring of the organ.

Last month, the U.S. health regulator approved Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for the condition that affects about 5% of adults in the United States.

The global market for NASH treatments is expected to surpass $16 billion by 2030, according to market research firm Vision Research Reports.

FXR314 also helped improve liver function with no worsening of scarring or fibrosis, Organovo said, adding that the drug was safe and well-tolerated.

In the 16-week study conducted with 214 patients, those who received 3 mg of FXR314 showed an average 22.8% reduction in liver fat, compared with 6.1% in the placebo group, Organovo said.

The company expects to present detailed findings of the study at an upcoming conference.

Related Posts

Remedium Lifecare ‘s Breakthrough: A New Era in Pharma

Mumbai: Remedium Lifecare Limited, a pivotal player in India’s pharmaceutical industry, has clinched a noteworthy contract with a UK-based pharmaceutical distribution firm, promising to amplify its stature in the global…

  • Pharma
  • February 18, 2025
  • 102 views
Bihar man booked in Haryana for online sale of abortion pills

The health department authorities in Yamunanagar and Gurugram districts of Haryana have lodged two first information reports (FIRs) against a Bihar-based illegal online distributor of medical abortion kits, a Schedule-H…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Remedium Lifecare ‘s Breakthrough: A New Era in Pharma

Remedium Lifecare ‘s Breakthrough: A New Era in Pharma

Bihar man booked in Haryana for online sale of abortion pills

Bihar man booked in Haryana for online sale of abortion pills

FDA busts spurious drug racket; medicines worth Rs 12.47 seized

FDA busts spurious drug racket; medicines worth Rs 12.47 seized

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance